Summary
The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinformatics, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) that will take advantage of the assets conferred by novel liquid biopsy strategies to provide complementary and comprehensive know-how on the features required to successfully fulfil the objectives of ColoMARK: 1) to foster a next generation of scientists that can address the challenges of colorectal cancer biomarker development. The network is enforced by pre-existing collaborations from COST Action TransColonCan, and enhanced by the participation of non-academic entities, who will play an essential role in the cross-sectoral and transversal training of the researchers. It is our purpose to provide a personalised training programme that builds on the knowledge offered by the participants to produce future cross-sectoral leadership and a sustainable initiative of excellent research that enhances the competitiveness of European researchers; 2) to achieve maximum impact by appropriate dissemination, patient and public engagement, and results exploitation, activities that will be embedded in the training of the researchers. Given the promising perspectives of liquid biopsy approaches for the future of cancer prevention and management, ColoMARK will constitute an opportunity to reach outstanding scientific, technological and societal impact in a field highly relevant to Horizon Europe´s priorities in cancer, therefore enhancing European competitiveness in R&I; 3) to advance in colorectal cancer understanding by producing outstanding, synergistic research. As the main scientific aim of ColoMARK, ten tailored ground-breaking research projects, only possible in the context of ColoMARK, will be undertaken for the identification and validation of better risk, prognostic and monitoring colorectal cancer biomarkers.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/101072448 |
Start date: | 01-11-2022 |
End date: | 31-10-2026 |
Total budget - Public funding: | - 2 656 677,00 Euro |
Cordis data
Original description
The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinformatics, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) that will take advantage of the assets conferred by novel liquid biopsy strategies to provide complementary and comprehensive know-how on the features required to successfully fulfil the objectives of ColoMARK: 1) to foster a next generation of scientists that can address the challenges of colorectal cancer biomarker development. The network is enforced by pre-existing collaborations from COST Action TransColonCan, and enhanced by the participation of non-academic entities, who will play an essential role in the cross-sectoral and transversal training of the researchers. It is our purpose to provide a personalised training programme that builds on the knowledge offered by the participants to produce future cross-sectoral leadership and a sustainable initiative of excellent research that enhances the competitiveness of European researchers; 2) to achieve maximum impact by appropriate dissemination, patient and public engagement, and results exploitation, activities that will be embedded in the training of the researchers. Given the promising perspectives of liquid biopsy approaches for the future of cancer prevention and management, ColoMARK will constitute an opportunity to reach outstanding scientific, technological and societal impact in a field highly relevant to Horizon Europe´s priorities in cancer, therefore enhancing European competitiveness in R&I; 3) to advance in colorectal cancer understanding by producing outstanding, synergistic research. As the main scientific aim of ColoMARK, ten tailored ground-breaking research projects, only possible in the context of ColoMARK, will be undertaken for the identification and validation of better risk, prognostic and monitoring colorectal cancer biomarkers.Status
SIGNEDCall topic
HORIZON-MSCA-2021-DN-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)